KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash from Investing Activities (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Cash from Investing Activities for 16 consecutive years, with -$741.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 2616.24% to -$741.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$545.8 million, a 107.75% decrease, with the full-year FY2025 number at -$545.8 million, down 107.75% from a year prior.
  • Cash from Investing Activities was -$741.8 million for Q4 2025 at Halozyme Therapeutics, down from $201.6 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $201.6 million in Q3 2025 to a low of -$741.8 million in Q4 2025.
  • A 5-year average of -$89.9 million and a median of -$44.9 million in 2021 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: crashed 8178.77% in 2023, then surged 455.57% in 2024.
  • Halozyme Therapeutics' Cash from Investing Activities stood at -$299.5 million in 2021, then surged by 99.42% to -$1.7 million in 2022, then plummeted by 374.86% to -$8.3 million in 2023, then soared by 455.57% to $29.5 million in 2024, then tumbled by 2616.24% to -$741.8 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Cash from Investing Activities are -$741.8 million (Q4 2025), $201.6 million (Q3 2025), and $84.8 million (Q2 2025).